Skip to content
Download PDF

Women's Health

Chapter 410 | Part 12: Endocrinology and Metabolism · Part 12 – Endocrinology & Metabolism · Chapter 410

Key Clinical Points

  1. Women live on average 5.9 years longer than men (79.1 vs. 73.2 years).
  2. CVD in women often presents with atypical symptoms (fatigue, nausea, indigestion) rather than chest pain.
  3. Triglycerides are an independent risk factor for CVD in women; low HDL and DM are more significant risks in women than in men.
  4. Takotsubo syndrome disproportionately affects postmenopausal women (80–90%).
  5. Aspirin is not effective for primary CVD prevention in women but significantly reduces ischemic stroke risk.
  6. Estrogen provides cardioprotective, anti-inflammatory, and antioxidant properties; its loss at menopause increases CVD risk and decreases bone density.
  7. Autoimmune disorders are more common in women due to the stimulatory effects of estrogens and inhibitory effects of androgens.
  8. Flibanserin (serotonin receptor agonist/antagonist) and Bremelanotide (melanocortin 4 receptor agonist) are used for HSDD.
  9. Pregnancy-related complications (preeclampsia, gestational DM) confer significant risk for CVD.
  10. Two-thirds of drug-induced torsades de pointes occur in women due to longer, more vulnerable QT intervals.

DEFINITION & OVERVIEW

• Sex vs. Gender: Distinction is critical for precision medicine. • Sex: Biological differences conferred by sex chromosomes and hormones. • Gender: Differences related to psychosocial roles and cultural expectations. • Policy: Since 2016, the NIH requires sex to be considered as a biological variable in study designs, analyses, and reporting.

Disease Risk: Reality and Perception

• Leading Causes of Death: Heart disease (1) and cancer (2) are the primary causes for both sexes. • COVID-19: Third leading cause of death in 2020 (>10% of all deaths). • Mortality Rates: Slightly lower in women (9.8%) than in men (10.9%). • Maternal Mortality: Higher in the US than other industrialized nations; associated with significant health disparities.

EPIDEMIOLOGY

• Menopause Timing: • Median age (Caucasian): 50–52 years. • Earlier onset: Hispanic, African-American, and lower socioeconomic status groups. • Impact: Risk for many diseases increases at menopause.

Mortality Data (Table 410-1)

• Comparison of Top 10 Causes of Death (2020): • Heart Disease: Women 20% | Men 22% • Cancer: Women 18% | Men 18% • COVID-19: Women 6% | Men 7.5% • Stroke: Women 10% | Men 4.1% • Alzheimer's Disease (AD): Women 6% | Men 2.3% • Chronic Lower Respiratory Disease (CLRD): Women 5% | Men 4.1% • Accidents: Women 4% | Men 10.9% • Suicide: Women 0% | Men 2.1% • Diabetes: Women 3% | Men 3.3% • All Other: Women 26% | Men 26.9%

Alzheimer's Disease (AD)

• Prevalence: Affects approximately twice as many women as men. • Risk Factors: • Age: Higher incidence in women even in younger groups (60–70 years). • Biomarkers: Earlier evidence of impaired cerebral glucose metabolism and reduced mitochondrial function in women. • Genetics: APOε4 allele is a major risk factor; strongly linked to sporadic AD in women.

Cardiovascular Disease (CVD)

• Trends: • Men: Deaths decreased markedly since 1980. • Women: Deaths only began to decrease substantially after 2000. • Stability: Since 2010, rates have stabilized or slightly increased in men. • Clinical Presentation: • Women with MI: More likely to present with cardiac arrest or cardiogenic shock. • Men with MI: More likely to present with ventricular tachycardia. • Age Factor: Younger women with MI are more likely to die than men of similar age.

ETIOLOGY & PATHOPHYISIOLOGY

• Sex Steroids & Metabolism: • Estrogen: Increases HDL, lowers LDL; provides direct vasodilation, enhances insulin sensitivity, and has anti-inflammatory/antioxidant properties. • Androgens: Have opposite effects on lipid metabolism. • Post-Menopause: Sharp drop in estrogen leads to increased CVD risk and rapid bone density loss.

Autoimmune Disorders

• Prevalence: More common in women (e.g., thyroid/liver diseases, Hashimoto's, Graves', SLE, RA, scleroderma, MS). • Mechanism: • Estrogens: Stimulate immunity. • Androgens: Inhibit immunity. • Genetics: X chromosome genes also contribute to sex differences.

Obesity and Metabolism

• Fat Distribution: • Women: Gluteal/femoral (gynoid) pattern; more subcutaneous fat. • Men: Central/android pattern. • Hormonal Interaction: • Women: Endogenous androgens \propto abdominal obesity; androgen administration → increased visceral fat. • Men: Endogenous androgens \propto inverse relationship with abdominal obesity. • Cancer Risk: Obesity increases breast and endometrial cancer risk in postmenopausal women via aromatization of androgens to estrogen in adipose tissue.

Osteoporosis

• Prevalence: \sim5x more common in postmenopausal women than age-matched men. • Mechanism: • Estrogen deficiency → increased osteoclast activity + decreased bone-forming units → net bone loss. • Development: Differences in bone mass exist as early as infancy; calcium intake during adolescence is critical for peak bone mass.

COVID-19 Pathophysiology

• Entry Mechanism: • ACE2 (membrane-bound) → primary entry point. • TMPRSS2 (serine protease) → viral priming/activation. • Sex Differences: • ACE2: Higher in men with diabetes and/or kidney disease. • TMPRSS2: More abundantly expressed in prostate tissue; regulated by androgenic ligands and AR binding.

CLINICAL FEATURES

• Cardiovascular Disease Symptoms: • Women: Less likely to have chest pain; more likely to present with fatigue, shortness of breath, indigestion/nausea, and anxiety. • Clinical Presentation: Angina was most common initial symptom in women; MI was most common in men. • Behavior: Women are less likely to contact 9-1-1 for these symptoms.

Alzheimer's Disease

• Estrogen Link: Women with AD have lower endogenous estrogen levels → hypothesis of neuroprotection. • Comparison: Other disorders (PD, ALS) show stronger association with male sex.

Sexual Dysfunction

• Intervention: Clitoral vacuum device may be used for arousal/orgasmic difficulties. • Mechanism: Increases cavernosal blood flow, engorgement, and vaginal lubrication.

DIFFERENTIAL DIAGNOSIS

• Takotsubo Syndrome: • Definition: Transient and resulting stress cardiomyopathy. • Prevalence: \sim2% of ACS patients; 80–90% are postmenopausal women. • Comparison: Mortality/morbidity higher in men (cardiogenic shock, cardiac arrest) than in women.

Autoimmune Disorders

• Common in Women: Thyroid/liver diseases, Hashimoto's, Graves', SLE, RA, scleroderma, MS. • More Common in Men: Ankylosing spondylitis.

INVESTIGATIONS & DIAGNOSIS

  1. Risk Assessment for CVD:
  2. Identify standard factors: Cholesterol, hypertension, smoking, obesity, low HDL, DM, physical inactivity.
  3. Identify female-specific/predominant factors: Pregnancy complications (preeclampsia, gestational DM), PCOS, RA, SLE.
  4. Specific Markers:
  5. Triglycerides → independent risk in women (not men).
  6. Low HDL & DM → more important risk factors in women than men.
  7. Hormone Therapy Evaluation:
  8. WHIMS Study: Estrogen alone or with progestin → increased risk for dementia/mild cognitive impairment.
  9. KEEPS Study: No adverse effect of HT on cognitive function.
  10. Conclusion: No evidence from placebo-controlled trials that HT improves cognition.
  11. Drug Metabolism Assessment:
  12. Factors: Women have lower body weight, smaller organs, higher % body fat, lower total-body water.
  13. Torsades de pointes: 2/3 cases occur in women due to longer, more vulnerable QT interval.

MANAGEMENT & TREATMENT

  1. Sexual Dysfunction Treatment:
  2. Flibanserin:
  3. Mechanism: Postsynamic agonist of 5-HT1A; antagonist of 5-HT2A.
  4. Requirement: REMS certification, written agreement to abstain from alcohol (risk of hypotension/syncope).
  5. Duration: Discontinue if no improvement after 8 weeks.
  6. Bremelanotide:
  7. Mechanism: Melanocortin 4 receptor agonist.
  8. Administration: Subcutaneous injection 45 min prior to sexual activity.
  9. Limits: Max one dose in 24h; max eight doses per month. Discontinue after 8 weeks without benefit.
  10. Note: PDE-5 inhibitors are not for FDS and should be discouraged.
  11. Cardiovascular Disease Management:
  12. Cholesterol drugs: Equally effective in both sexes.
  13. Aspirin: Not effective for primary prevention in women → but significantly reduces ischemic stroke risk.
  14. Hormone Therapy (HT):
  15. Findings: No benefit for primary/secondary prevention of CVD.
  16. CEE + MPA: Associated with increased risk for CVD (especially 1st year) and ischemic stroke.
  17. CEE alone: Neither increased nor decreased CVD risk.
  18. Exception: Younger age (50–59) + BSO → >30% reduction in all-cause mortality with CEE.
  19. Obesity Pharmacotherapy:
  20. Semaglutide: Women showed greater average weight reduction than men.
  21. Reasons: Lower baseline weight, different eating behaviors (hormone regulated), different gastric emptying rates.

Table 2: Pharmacologic Agents for HSDD

• Flibanserin: - Mechanism: Postsynaptic agonist of serotonin receptor 1A; antagonist of serotonin receptor 2A. - Side Effects: Nausea, fatigue, sleepiness, insomnia, hypotension, dizziness (with alcohol). - Note: REMS required. Abstain from alcohol. • Bremelanotide: - Mechanism: Melanocortin 4 receptor agonist. - Side Effects: Nausea (40%), facial flushing (20%), headache (10%). - Dosing: Subcutaneous injection 45 min prior to sexual activity. Max 1/day, max 8/month.

COMPLICATIONS & PROGNOSIS

• Diabetes and CVD: - Women with DM: 6x greater risk of dying from CVD compared to women without DM. - Premenopausal women with DM: Lose cardioprotective effect of female sex; have rates of CVD identical to males. - Clinical findings in DM: Impaired endothelial function, reduced coronary vasodilatory response, more likely to have LVH. • Alzheimer's Disease Prognosis: - Depression in women: Worse prognosis than in men (longer duration, lower rate of spontaneous remission).

• Trends: - Men: Marked decrease since 1980. - Women: Significant decrease only after 2000. - Clinical Presentation: - Women with MI → more likely to present with cardiac arrest or cardiogenic shock. - Men with MI → more likely to present with ventricular tachycardia.

SPECIAL CONSIDERATIONS

• Pregnancy and Reproductive History: - High Risk (≥1.5x): Pre-eclampsia, gestational DM, hypertension, premature ovarian insufficiency, placental abruption. - Low Risk (<1.5x): Early menarche, early menopause, parity, polycystic ovary syndrome. • HIV Infection: - Clinical differences: Women have more rapid CD4 decline; more frequent candidiasis; less common Kaposi's sarcoma. - Drug reactions: More adverse reactions (lipodystrophy, dyslipidemia, rash) due to higher plasma concentrations in women. • COVID-19: - Severity: Higher incidence of infection, ICU admission, and case-fatality rates in men. - Age factor: More pronounced sex differences observed in older age groups.

KEY PEARLS & HIGH-YIELD POINTS

• Clinical Pearls: - Women live 5.9 years longer than men. - Maternal mortality is rising since 2000. - Estrogen deficiency → increased osteoclast activity/decreased bone-forming units. - Triglycerides are an independent risk factor for CVD in women (not men). - Aspirin: Not for primary prevention of CVD in women, but reduces ischemic stroke risk. • Clinical Traps: - Misconception that women are at lower risk for CVD → leads to fewer interventions. - Providers less likely to suspect CVD in women → fewer acute interventions. - Women less aware of differing prodromal symptoms (fatigue, nausea vs. chest pain). - Depression in women has a worse prognosis than in men.